Madagascar vs Palau: Hepatitis B surface antigen (HBsAg) prevalence
Madagascar
0.6%
in 2024
Palau
0.6%
in 2024
Madagascar rank
51st
Palau rank
51st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Madagascar
- Palau
How they compare
Madagascar currently reports 0.6% against 0.6% in Palau, a difference of 0.0%.
Across all 10 years both countries report, Palau has been ahead every year.
Madagascar ranks 51st and Palau ranks 51st of 194 countries.
Palau has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Madagascar | Palau | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.6% | 1.2% | 0.5% | Palau |
| 2020s | 0.5% | 0.7% | 0.1% | Palau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Madagascar or Palau?
- Madagascar, at 0.6% against 0.6% in Palau as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Madagascar and Palau?
- 0.0%, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Palau?
- 10 years are reported by both, from 2015 to 2024.
- How do Madagascar and Palau rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Madagascar ranks 51st and Palau ranks 51st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.